131 related articles for article (PubMed ID: 8601221)
1. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up.
Levine AM; Groshen S; Allen J; Munson KM; Carlo DJ; Daigle AE; Ferre F; Jensen FC; Richieri SP; Trauger RJ; Parker JW; Salk PL; Salk J
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):351-64. PubMed ID: 8601221
[TBL] [Abstract][Full Text] [Related]
2. Salk's HIV immunogen: an immune-based therapy in human trials since 1988.
Crit Path AIDS Proj; 1994-1995 Winter; (No 30):1, 20-3. PubMed ID: 11362152
[TBL] [Abstract][Full Text] [Related]
3. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300.
Churdboonchart V; Sakondhavat C; Kulpradist S; Na Ayudthya BI; Chandeying V; Rugpao S; Boonshuyar C; Sukeepaisarncharoen W; Sirawaraporn W; Carlo DJ; Moss R
Clin Diagn Lab Immunol; 2000 Sep; 7(5):728-33. PubMed ID: 10973445
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization.
Gringeri A; Santagostino E; Mannucci PM; Tradati F; Cultraro D; Buzzi A; Criscuolo M; David A; Guillemot L; Barré-Sinoussi F
J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):978-88. PubMed ID: 7914235
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial.
Turner JL; Trauger RJ; Daigle AE; Carlo DJ
AIDS; 1994 Oct; 8(10):1429-35. PubMed ID: 7818813
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
[TBL] [Abstract][Full Text] [Related]
8. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells.
Trauger RJ; Ferre F; Daigle AE; Jensen FC; Moss RB; Mueller SH; Richieri SP; Slade HB; Carlo DJ
J Infect Dis; 1994 Jun; 169(6):1256-64. PubMed ID: 7910836
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization.
Robbins GK; Addo MM; Troung H; Rathod A; Habeeb K; Davis B; Heller H; Basgoz N; Walker BD; Rosenberg ES
AIDS; 2003 May; 17(8):1121-6. PubMed ID: 12819512
[TBL] [Abstract][Full Text] [Related]
10. Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand.
Churdboonchart V; Moss RB; Sirawaraporn W; Smutharaks B; Sutthent R; Jensen FC; Vacharak P; Grimes J; Theofan G; Carlo DJ
AIDS; 1998 Aug; 12(12):1521-7. PubMed ID: 9727574
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative.
Bartlett JA; Wasserman SS; Hicks CB; Dodge RT; Weinhold KJ; Tacket CO; Ketter N; Wittek AE; Palker TJ; Haynes BF
AIDS; 1998 Jul; 12(11):1291-300. PubMed ID: 9708408
[TBL] [Abstract][Full Text] [Related]
12. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.
Moss RB; Giermakowska W; Lanza P; Turner JL; Wallace MR; Jensen FC; Theofan G; Richieri SP; Carlo DJ
Viral Immunol; 1997; 10(4):221-8. PubMed ID: 9473153
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of HIV-1-infected Thai patients immunized with Remune monotherapy.
Sukeepaisarncharoen W; Churdboonchart V; Kulpradist S; Isarangkura Na Ayudthya B; Rugpao S; Chandeying V; Sirawaraporn W; Carlo D; Moss RB
HIV Clin Trials; 2001; 2(5):391-8. PubMed ID: 11673813
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of HIV-seropositive patients: preliminary report on a dose-ranging study.
Slade H; Turner J; Abrams C; Carlo D; Salk J
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1329-31. PubMed ID: 1361349
[No Abstract] [Full Text] [Related]
15. Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects.
Fernandez-Cruz E; Moreno S; Navarro J; Clotet B; Bouza E; Carbone J; Peña JM; Pérez Molina J; Podzamczer D; Rubio R; Ocaña I; Pulido F; Viciana P; Maradona JA; Blazquez R; Barros C; Quereda C; Rodriguez-Sainz C; Gil J; Abad ML; Díaz L; Cantó C; Muñoz MA; Ferrer E; Jou A; Sirera G; Díaz M; Lopez F; Gatell JM; Gonzalez-Lahoz J;
Vaccine; 2004 Aug; 22(23-24):2966-73. PubMed ID: 15297045
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial.
Trauger RJ; Daigle AE; Giermakowska W; Moss RB; Jensen F; Carlo DJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S74-82. PubMed ID: 7552517
[TBL] [Abstract][Full Text] [Related]
17. In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune).
Moss RB; Wallace MR; Lanza P; Giermakowska W; Jensen FC; Theofan G; Chamberlin C; Richieri SP; Carlo DJ
Clin Diagn Lab Immunol; 1998 May; 5(3):308-12. PubMed ID: 9605982
[TBL] [Abstract][Full Text] [Related]
18. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen.
Patterson BK; Carlo DJ; Kaplan MH; Marecki M; Pawha S; Moss RB
AIDS; 1999 Sep; 13(13):1607-11. PubMed ID: 10509560
[TBL] [Abstract][Full Text] [Related]
19. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant.
Moss RB; Webb E; Giermakowska WK; Jensen FC; Savary JR; Wallace MR; Carlo DJ
J Acquir Immune Defic Syndr; 2000 Jul; 24(3):264-9. PubMed ID: 10969351
[TBL] [Abstract][Full Text] [Related]
20. Inactivated HIV-1 Immunogen: impact on markers of disease progression.
Moss RB; Ferré F; Trauger R; Jensen F; Daigle A; Richieri SP; Carlo DJ
J Acquir Immune Defic Syndr (1988); 1994; 7 Suppl 1():S21-7. PubMed ID: 7910207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
